You need to include long term debt into discussion if you based your evaluation on the cash in hand. The evaluation is linked to the value of both drugs they have. I apparently give it much higher evaluation as my average cost is $3.2 per share and I have 10K of them. Lets see if prescription obesity drug market is going to be developed faster now two of the drugs have been on the market for more than one year, safety concern should be out of window by now. I think that most of people still think that over-weight people can just exercise and eat better food and lose weight that way. My thinking is if that is the true why there are so many over-weight people. Everywhere I look at, I see a lot potential customers for the obesity drug companies that I have positions. But the real users are not that many. Are these drugs too expensive or are they just misunderstood or the doctors do not recognize that people do not just go exercise and eat better all the sudden?
Quite. Don't tell him that most Chinese-related solar companies are severely undervalue due to oil or AD or that black dude on TV. But they have been all running at full capacity for Q4 14 and Q1 15 due to high demand. Profit might not be as high as analysts expected due to exchange rate but will be much better than bears give credit for.